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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) has 
considerable effects on cardiac function, including those of the right 
ventricle, left ventricle and pulmonary blood vessels. 
Chronic Obstructive Pulmonary Disease (COPD), a common 
preventable and treatable disease is characterised by persistent air flow 
limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and lungs to noxious 
particles or gases. Exacerbations and comorbidities contribute to the 
overall severity in the individual patients. 
 COPD is one of the leading causes of morbidity and mortality 
worldwide and results in an economic and social burden. The global 
burden of disease study projected that COPD, which ranked sixth as a 
cause of death in 1990 will become the third leading cause of death 
worldwide by 2020. Many patients with COPD have comorbidities 
that have a major impact on quality of life and survival. 
Airflow limitation and particularly hyperinflation affect cardiac 
function and gas exchange. Pulmonary hypertension may develop late 
in the course of COPD and is mainly due to hypoxic vasoconstriction 
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of small pulmonary arteries, eventually resulting in structural changes 
that include intimal hyperplasia and later smooth muscle 
hypertrophy/hyperplasia. The loss of pulmonary capillary bed in 
emphysema may also contribute to increased pressure in the 
pulmonary circulation. Progressive pulmonary hypertension may lead 
to right ventricular hypertrophy and eventually to right sided cardiac 
failure. 
Progressive impairment of left ventricular diastolic function 
correlates with the severity of pulmonary Hypertension. It is likely 
that this results in large part from bulging of the inter ventricular 
septum from the hypertrophied and dilated right ventricle into the 
cavity of the left ventricle. 
Most of the increased mortality associated with COPD is due to 
the cardiac involvement. Echocardiography provides a rapid, non-
invasive, portable and accurate method to evaluate the cardiac 
changes. In South India, studies are not found easily related to 
cardiovascular abnormalities in mild to very severe COPD. This study 
is to find out the specific effects on the right ventricle, left ventricle 
and pulmonary blood vessels due to COPD and their relation to its 
severity.  
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AIM 
 
1. To assess the cardiovascular changes secondary to COPD by 
echocardiography. 
2. To find out the correlation between the cardiovascular changes 
and the severity of COPD  
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REVIEW OF LITERATURE 
Definition of COPD as per Gold Report 2011:  
“Chronic Obstructive Pulmonary Disease (COPD), a common 
preventable and treatable disease, is characterized by persistent air 
flow treatable disease, is characterized by persistent airflow limitation 
that is usually progressive and associated with an enhanced chronic 
inflammatory repose in the airways and the lung to noxious particles 
and gases. Exacerbations and co-morbidities contribute to the overall 
severity in individual patients”. 
Natural History 
Factors contributing to the history of COPD include 
embryologic events such as intrauterine lung development, childhood 
and adolescent lung growth and adult lung exposures. Hence the 
natural history of COPD extends over the entire life span of an 
individual. A longitudinal study by Fletcher and colleagues for 8 years 
on natural history of COPD explains several key clinical issues. This 
study commonly called a “Fletcher-Peto curve,” plots FEV1 versus 
age. But, this study was limited by the fact that it did not consider the 
non-smokers with COPD and the extra pulmonary effects of COPD. 
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Several ongoing longitudinal studies on COPD patients over 
time help to define the “Fletcher-Peto curve” by tracking other 
features of the COPD, effects outside the lung and for exposures other 
than cigarette smoking. (7) 
Over a life time of 50 years a normal individual can lose 1 L of 
FEV1, declining at an average of 20 mL/yr, but this decline accelerates 
with increasing age. 
Cigarette Smoking 
Cigarette Smoking impacts natural history of COPD in several 
ways. Smoking reduces maximally attained lung function, “plateau 
phase” is reduced in duration and may be absent and the rate at which 
lung function declines is probably increased. As a result an average 
smoker loses about 2 L of FEV1 over a period of 50 years with an 
average decline of about 40 mL/yr. This decline in lung function may 
not be continuous. In some cases the decline may be stepwise where 
the individual’s lung function was acutely impacted by exacerbations. 
In some individuals decline in lung function may be rapid. 
Individuals with a low FEV1 will have a more rapid decline of FEV1 
and have more chance of developing COPD when compared to 
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individuals with a more normal FEV1, a prediction known as the 
“horse-racing effect” (according to which, at any point in a race, the 
horse in the lead was the fastest, will continue to be the fastest, and is 
more likely to win). (8). Cessation of smoking habit during adult years 
can slow the rate of decline among patients with mild COPD. 
Early Disease  
Treatment goals in COPD mainly focus on alleviation of 
symptoms. Because patients with early disease are often 
asymptomatic, the importance of identifying individuals with early 
disease usually was not recognized. However, individuals with mild 
COPD have increased mortality, which is mainly due to acute cardiac 
events. This is true for both smokers and non smokers. The 
relationship between cardiac events and mild COPD may be due to 
systemic inflammation. Identifying a group of individuals with 
increased cardiac risk, and identifying that they may need treatment by 
exercise training program, has potential clinical benefit.  
Advancing Disease  
As FEV1 declines, risk for mortality increases. Cardiac events 
still remain a major cause of death, even in severe COPD, as the 
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severity of lung function compromise increases, the relative incidence 
of death due to respiratory causes, increases. During exacerbations, 
individuals are at particular risk for death. 
Mortality is also increased in those who have recovered from an 
exacerbation. In the SUPPORT (Study to Understand Prognoses and 
Preferences for Outcomes and Risks of Treatments) trial, the 2-year 
mortality rate for patients who are admitted for acute exacerbation of 
COPD with CO2 retention was 49%. But, studies from several places   
have shown that some patients with more severe obstructive airway 
disease can survive for many years.  
Thus, it is impossible to predict the course of an individual with 
certainty. Decisions relating giving care and end-of-life issues must be 
individualized and also must be based on all other factors in addition 
to lung function.  
Pathophysiology of the Pulmonary Circulation 
The normal pulmonary circulation, which is composed of good 
compliant pulmonary arteries and a rich capillary network with a large 
capability for recruitment, can accommodate high increases in blood 
flow (e.g., with left-to-right congenital intra cardiac shunts or during 
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exercise) without a significant rise in pulmonary arterial pressure. For 
example, this capillary reserve can be showed in a healthy person 
during cardiac catheterization by transient balloon occlusion of the 
right or left main pulmonary artery. Only a small rise or no rise in the 
resting pulmonary arterial pressure results,  in spite of  the fact that the 
entire cardiac output must  go through the pulmonary circulation of 
only one lung. Thus, after recovering from pneumonectomy, patients 
usually have only slightly raised resting pulmonary arterial pressure. 
Oxygen is the major mediator of pulmonary autoregulation, 
with vasoconstriction occurring in lung regions that are poorly 
oxygenated and pulmonary vasodilation occurring in regions where 
the partial pressure of oxygen is high and the blood flow is directed 
preferentially to the areas which are better oxygenated. Hypoxic 
pulmonary vasoconstriction is the major mechanism reasoned for the 
development of pulmonary hypertension in patients with lung disease; 
but, significant structural changes within the pulmonary vascular tree 
can also occur, which lead to the pulmonary capillary bed destruction 
and contribute to the development of pulmonary hypertension. Earlier 
in the natural history of lung diseases, the resting pressure in the 
pulmonary artery is normal usually, and because of the large capillary 
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reserve within the lung, it may not be readily detectable that 
significant capillary destruction occurs until almost half of the 
capillary bed is destroyed. 
The pathophysiology of pulmonary hypertension associated 
with severe respiratory diseases is generally distinct from that of the 
pulmonary arterial hypertensive disorders, though they  share some 
similar mechanistic pathways. The vascular remodelling process in 
pulmonary arterial hypertension and interstitial lung disease involve 
changes in all three portions of the vessel wall: the adventitia, media, 
and intima. But so, unlike the pulmonary arterial hypertensive 
disorders, in which marked intimal proliferation adventitial 
extracellular matrix and collagen deposition, and plexigenic lesions 
are seen, such severe findings are not usually present in patients with 
pulmonary hypertension associated with chronic restrictive or 
obstructive lung disorders. 
Hypoxic Pulmonary Vasoconstriction 
Many stimuli may result in pre capillary pulmonary 
vasoconstriction with resultant pulmonary hypertension. Out of these, 
the most important and the most potent, alveolar hypoxia may be 
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present under many circumstances. Pulmonary vasoconstriction may 
occur in perfectly healthy lungs. The pulmonary hypertension 
observed in persons living at high altitudes is caused by chronic 
hypoxemia although the presence of hyperventilation with resultant 
hypocapnia would be there. Like that, hypoventilation   sufficient to 
produce alveolar hypoxia and hypercapnia, which can occur in 
morbidly obese patients, results in pulmonary hypertension that is 
secondary to pulmonary vasoconstriction.  
Other causes of primary hypoventilation, whether it arises 
centrally or from respiratory muscle weakness, can also cause 
pulmonary hypertension secondary to inadequate alveolar ventilation. 
Hypercapnia, which is primarily mediated by an increase in hydrogen 
ion concentration, aggravates pulmonary vasoconstriction, enhancing 
the pressure increase expected from a reasonable degree of hypoxia 
alone. 
The consequences of hypoxic pulmonary vasoconstriction in 
healthy residents who are residing at high altitude and in COPD 
patients with corpulmonale residing at sea level may be compared. In 
the former case, a combination of alveolar hypoxia, hyperventilation, 
and hypocapnia is seen; in the latter case, hypoxia is usually 
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associated with hypoventilation and hypercapnia. Subjects residing at 
high altitudes would have a decreased plasma volume and increased 
hematocrit. Their stroke volume and cardiac output predisposed to be 
low. But in contrast, patients with COPD seem to have normal or 
increased blood volume, and their cardiac output is usually normal or 
even elevated. Healthy subjects, even who are residing at very high 
altitudes, usually do not develop right ventricular failure inspite of the 
presence of hypoxia and pulmonary artery hypertension, which 
suggests that acidemia and hypercapnia are vital contributing elements 
to impaired right ventricular function in  COPD patients. Low alveolar 
pO2 increases pulmonary arterial pressure in a hyperbolic dose-
response curve, with which the pressure rises much more rapidly when 
the arterial PO2 values fall below 75 mm Hg.  
There is still a marked individual variability in the level of 
pulmonary arterial pressure at a given high altitude. Somewhat, this 
may be elucidated by differences in individual sensitivity to 
ventilatory drive which is produced by hypoxia, with some persons 
hyperventilating more than others. But, some of the variability 
depends on the difference in pulmonary vasoconstrictive response, 
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which apparently reflects an inherited difference in reactivity of 
pulmonary vasculature. 
 This viewpoint is sustained by observations of the high-altitude 
pulmonary hypertensive disease in cattle known as brisket disease. 
When cattle native to low altitudes are exposed to high altitudes for 
grazing, pulmonary arterial pressure climbs only moderately in some; 
but in others the pressure raises steeply. Cattle with either 
hyporesponsive or hyperresponsive pulmonary vascular reactivity 
transmits these phenotypes from parents to offspring as a genetic trait. 
Like as it has been suggested that genetic traits can play a role in the 
pulmonary pressor response to the hypoxia of high altitude, an 
explanation for the consideration that some patients with COPD 
develop pulmonary hypertension, but others do not, assigns this 
variability to inherited differences in pulmonary vascular reactivity or 
in the ventilatory sensitivity to hypoxia and carbon dioxide,                  
or both (9). 
Most of the patients who develop pulmonary hypertension at 
rest with COPD are both hypoxemic and hypercarbic. As assumed, the 
hypercarbic patients have a low ventilatory sensitivity to carbon 
dioxide, because, hypoxemic residents at high altitudes hyperventilate 
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and are hypocarbic. It is thus explained that some patients who have a 
normal ventilatory sensitivity to carbon dioxide and hypoxia have a 
raised ventilatory effort in response to obstructive lung disease and so, 
normal blood gases would be maintained. In contrast, a patient who 
responds with a low ventilatory sensitivity don’t compensate and 
therefore develops an insufficient ventilatory drive to escape airway 
resistance, finally causing hypercapnia, hypoxemia, and pulmonary   
vasoconstriction. 
Apparently all COPD patients, whether characterized by the 
now obsolete terms “pink puffers” and “blue bloaters,” have more 
drive to breathe when observed by the mouth occlusion pressure 
(P0.1) test. The clinical differences between the groups are now 
accepted to result from differences in the breathing pattern and, may 
be, in intrapulmonary gas exchange.  However, generally the more 
abnormal the PO2 and PCO2 values in COPD patients, the more 
severe the pulmonary hypertension and polycythemia and more 
chance of corpulmonale. 
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Pulmonary Vascular Remodelling 
The presence of chronic hypoxemia and ventilatory inadequacy 
in patients with chronic respiratory diseases usually lead to pulmonary 
vascular remodelling, which is characterized by distal smooth muscle 
proliferation with neomuscularization of normally unmuscularized 
small pulmonary vessels, prominent medial smooth muscle 
hypertrophy, and mild intimal changes. Hypoxic vasoconstriction raise 
the pulmonary vascular resistance and pressure, shear force, and wall 
stress, and so, these mechanical forces  lead to a cascade of mediators 
and cellular changes which contribute to the remodelling process. 
COPD is the most common and frequently studied lung disease 
associated with pulmonary hypertension and corpulmonale.  Well 
known structural changes occur in the pulmonary circulation in COPD 
patients. The presence of hypoxemia and chronic ventilatory 
inadequacy is associated with hypoxic pulmonary vasoconstriction 
and early changes of intimal proliferation with medial hypertrophy in 
the small branches of the pulmonary arteries. Vascular smooth muscle 
cells are laid down transversely within the intima, and hypertrophy of 
these cells and smooth muscle cells within the media are seen. 
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Localized thrombosis in situ may occur, obliterating parts of the 
pulmonary vascular tree. 
 Progressive destruction of capillaries which course along 
alveoli which are being destroyed or coalescing into bullae   
diminishes further, the cross-sectional area of the pulmonary vascular 
tree. (10).The structural changes together with the vasoconstrictive 
effects result in a noted increase in pulmonary vascular resistance. The 
result is pulmonary arterial hypertension, which in itself can cause 
further structural damage to the smaller branches of the pulmonary 
circulation and present as a stimulus for the development of medial 
hypertrophy and dilation of the larger branches of the pulmonary 
artery. If these changes are longstanding, prominent atherosclerotic 
changes can be seen in the main pulmonary artery and its main 
branches. 
Role of Inflammation 
COPD is defined as an inflammatory airways disease and in 
both asymptomatic smokers and patients with COPD, the 
inflammatory reaction has been well characterised in central and 
peripheral airways, as well as in the alveolar spaces and septae. In 
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non-hypoxemic patients with mild to moderate COPD, Peinado and 
his colleagues found that the number of inflammatory cells, mainly T 
lymphocytes (CD8+) was increased in Pulmonary artery of COPD in 
comparison with non-smokers and smokers who have normal lung 
function (11,12). The intensity of the inflammatory infiltrate 
corresponds to both the endothelium-dependent relaxation and the 
intimal thickening and was also abnormal even in smokers with 
normal lung function. Thus, smoking-induced inflammatory changes 
are important. Studies done in murine model suggest the role of the 
proinflammatory cytokine, IL-6 in the pulmonary vascular 
remodelling. In patients having COPD and PH, IL-6 levels were 
reported to be raised in those with genotype IL-6 GG and 5-HTT LL 
additionally more likely to have pulmonary hypertension. 
The association of pulmonary hypertension with interstitial lung 
disease (ILD) is less well characterized when compared with that of 
COPD; recent studies have led to a better understanding of the 
pathophysiologic mechanisms involved in the development of 
pulmonary hypertension in these patients. The most common ILDs 
associated with pulmonary hypertension include connective tissue 
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disease–related ILD, idiopathic pulmonary fibrosis, sarcoidosis and 
histiocytosis X. 
The degree of pulmonary hypertension seen in COPD patients 
and cystic fibrosis is generally, reported to be mild or moderate, often 
paralleling the degree of hypoxemia.  In a cohort study of 500 patients 
with COPD and corpulmonale, Stevens and colleagues observed that 
only 6 patients had severe elevations of pulmonary arterial pressure, 
defined as mean pulmonary arterial pressure greater than 50 mm Hg, 
and that the increase in the severity of pulmonary arterial pressure did 
not seem to be related to the severity of underlying lung disease. 
Henceforth, the direct correlation between arterial PO2 and 
pulmonary arterial pressure is not good. In a study of 120 patients with 
severe emphysema assessed for entry into the National Emphysema 
Treatment Trial, multiple stepwise regression analysis showed that 
arterial PO2 was not an independent predictor of mean pulmonary 
arterial pressure, and that the indices of emphysema severity and 
pulmonary arterial pressure did not correlate with each other. 
Studies in patients with ILD revealed that the presence of 
pulmonary hypertension does not seem to correlate well with lung 
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volumes, whereas impairment of diffusion (reduced transfer factor for 
carbon monoxide) and the oxygen supplementation need were 
predictors of pulmonary hypertension. 
Several studies recommend that vascular remodelling in patients 
with mild COPD without concomitant hypoxemia is a component of 
early-stage disease as witnessed by increased inflammatory cell 
density in the adventitia and increased intimal thickness of pulmonary 
arteries. Further, endothelial lesions have been observed to be present 
in cigarette smokers without chronic airflow obstruction. 
A study investigated the development of pulmonary arterial 
hypertension in patients with moderate to severe airflow obstruction 
who neither had resting pulmonary arterial hypertension nor met 
criteria for long-term oxygen therapy ; 76 of 131 (58%) had exercise-
induced pulmonary arterial hypertension at the initiation of the study. 
Five years later,  25%  of  the  subjects  had  evolved  resting  
pulmonary  arterial hypertension, including 32% of subjects who had 
exercise-induced pulmonary arterial hypertension at baseline.  These 
studies imply that factors other than hypoxemia alone are responsible 
for the development of pulmonary vasoconstriction and remodelling 
finally leading to pulmonary arterial hypertension. 
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RIGHT VENTRICLE  
The normal right ventricle is crescent shaped and the thickness 
of right ventricular wall is less than 0.6 cm. In men it weighs usually 
less than 65 g in, and in women it is less than 50 g. 
The embryological development of   right ventricle is from two 
components: the bulbus cordis and sinus venosus. Bulbus cordis forms 
the outflow tract, and the sinus venosus forms the inflow tract. Both 
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these are separated by a muscular ridge namely crista 
supraventricularis. 
The right ventricle contracts sequentially from inflow to 
outflow in normal heart. This results in the effective emptying of its 
volume into the low-impedance pulmonary circulation.  In accordance 
with venous return and Starling`s law of the  heart ,the right ventricle 
plays an almost passive role in maintaining the  cardiac output in 
absence of cardiac disease. 
In congenital tricuspid atresia, Fontan procedure, an early 
surgical intervention involved right ventricular bypass through 
anastamosis between right atrium and the pulmonary artery .This 
resulted in the perfusion of   pulmonary circulation  from  high  central 
venous pressure.  It is to be  noted  that a  reduced  survival  rate is 
observed in those with right ventricular damage caused by  elevated  
central venous pressures which was resulted  from  an  inferior 
myocardial infarction. 
It is difficult to measure accurately the right ventricular volume  
by radiographic or echocardiographic techniques due to its shape. In a 
series of 15 subjects without heart disease, right ventricular end-
diastolic volume measured in supine position by a thermo dilution 
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technique, which should have overestimated volumes, averaged 103 ý 
24.4 ml/m2. With passive assumption of an upright posture , right 
ventricular end-diastolic volume falls because of gravitational pooling 
of blood within the distensible venous tree. In a separate series of 8 
subjects without heart disease, end-diastolic volume declined a mean 
of 16.3 ml/m2 from a mean baseline of 98.1 ý 23.3 ml/m2. 
The end-diastolic fibre stretch becomes less due to fall in right 
ventricular end-diastolic volume and this results in a decrease in   
stroke volume on upright position. Aortic baroreceptor stimulation at 
the same time reflexively raises heart rate by  about 12 beats/min, and 
thus compensates for a stroke volume fall of about 13.3 ml/m2; hence 
cardiac output is maintained at the same range as in a recumbent 
patient at rest. 
A significant fall in stroke volume results due to acute increases 
in right ventricular afterload. Contrastly, the left ventricle   
accommodates an acute increase in after load with only little change  
in stroke volume. Uniform hypertrophy of the right ventricle results 
from chronic pulmonary hypertension along with increase in right 
ventricular work. Due to this, the   right ventricular weight increases 
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as right ventricular wall myocytes thicken and the nuclei enlarges. 
Interstitial fibrosis occurs.  
As the ventricular hypertrophy increases, the ability to expel the 
stroke output against high pulmonary vascular resistance increases and 
thus maintains the cardiac output.  Pulmonary artery systolic pressure 
was observed to be significantly higher than the systemic pressure in 
patients having idiopathic pulmonary hypertension or severe mitral 
stenosis and pulmonary vascular disease. 
The increase in right ventricular work along with pulmonary 
hypertension produces a significant increase in myocardial oxygen 
consumption of right ventricle. Right ventricular endocardial coronary 
perfusion is decreased due to wall thickening.  End-diastolic pressure 
increases due to increasing right ventricular stiffness during diastole, 
and thus compromising endocardial coronary perfusion.  These factors 
produce an imbalance between right ventricular myocardial oxygen 
demand and supply.  
In studies based on end-diastolic pressure-volume relationship, 
in the presence of pulmonary hypertension, COPD patients had well-
preserved right ventricular contractility.  Presence of acidemia or 
infection precipitates right ventricular failure. The right ventricle is 
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unable to increase its work and the end-diastolic pressure increases in 
patients with alveolar hypoventilation in the presence of chronic 
hypercapnia with acidosis.  
The myocardial contractility impairment in the presence of 
hypercapnia plays a vital role in causing decompensated pulmonary 
heart disease in case of acute increases in arterial PCO2 during 
exacerbations of COPD and decreases in alveolar ventilation.  Right 
ventricular and pulmonary artery systolic pressures show pulsus 
alternans which is similar to that of left ventricular failure.  
The right ventricular volume overload along with ventricular 
dilation decreases the ejection fraction, because stroke volume is 
maintained close to the normal range in decompensated 
corpulmonale.  Right ventricular afterload increases on exercise in 
COPD patients, which   increases right ventricular end-diastolic 
volume and ejection fraction decreases. This limits the normal 
exercising ability of such patients.    
 
 
Right ventricular dilation and wall thinning increases right 
ventricular wall stress and that, along with increased heart rate, 
increases myocardial oxygen consumption. Increased myocardial 
oxygen consumption along with decreased myocardial perfusion 
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results in right ventricular ischemia and deterioration of right 
ventricular function. 
 As pulmonary pressure increases and the right ventricle dilates, 
severe tricuspid regurgitation occurs, thus limiting left ventricular 
filling. Further right ventricular dilation with intact pericardium 
compromises left ventricular filling. The interventricular septum shift 
towards the left ventricle and intrapericardial pressure raise reduces 
left ventricular distensibility and   filling pressure, which represents 
the true preload. 
Decreased left ventricular preload compromises the systemic 
cardiac output initially with exercise and eventually  at rest.  In 
patients with a patent foramen ovale, increasing right atrial pressures 
cause significant right-to-left atrial shunting  and thus causes systemic 
oxygen desaturation and further worsens systemic oxygen delivery. 
LEFT VENTRICLE  
It was uncertain whether left ventricular failure occurs 
following right ventricular failure resulting from 
corpulmonale. This was due to the fact that earlier studies of COPD 
patients with corpulmonale included chiefly middle-aged or older 
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men with a smoking history and were likely to have associated 
coronary artery disease.  
Left ventricular failure in some of these patients may have 
been resulted from coexisting coronary artery disease.  Cardiac 
catheterization studies showed abnormal left ventricular end-
diastolic pressure-volume relationships even with normal left 
ventricular performance. (13,14). 
Echocardiographic studies revealed impairment of left 
ventricular diastolic function correlated with the severity of 
pulmonary hypertension. .This results largely from the bulging of  
interventricular septum from the hypertrophied and dilated right 
ventricle into the left ventricular cavity, and ventricular 
interdependence exerted by pericardial constraint.  (15). 
Left ventricular diastolic geometry becomes distorted and 
there is alteration of filling characteristics  such that a higher filling 
pressure is needed to produce the same end-diastolic fibre stretch 
that is needed for a given stroke work, according to  Starling's law 
of the heart.   
Pulmonary artery wedge pressure which is a reflection of left 
heart filling pressure gets distorted due to increased intra-alveolar 
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pressures, and large swings in intrathoracic pressure. This produces 
large fluctuations in wedge pressure tracings in COPD patients, and 
increases intrapericardial pressure. This is difficult when the patient 
receives positive end-expiratory pressure from a mechanical 
ventilator. 
In severe right heart failure with increase in right atrial pressure, 
coronary sinus pressure increases. This results in an increase in left 
ventricular wall dimension and thus limiting distensibility of left 
ventricle. The mechanism causing reduced left ventricular preload acts 
independently of diastolic ventricular interaction caused by 
enlargement of right ventricle  enlargement. 
Recent studies have shown that left ventricular dysfunction is 
associated with increased arterial stiffness, independent of the 
mechanisms mentioned above. Left ventricular dysfunction alone has 
also been reported in some cases, might be because of these arterial 
stiffness measured by pulse wave velocity. 
One study posted in Eur Respir Journal in the 2012 observed 
that cardiac changes are highly prevalent in patients with COPD 
during their first severe exacerbation. These patients did not have any 
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cardiac ailments before or any other risk factors for cardiovascular 
disease. (1) 
SYMPTOMS AND SIGNS  
Mild pulmonary hypertension reflected in small chronic 
elevations in right ventricular pressure usually causes minimal 
clinical, radiologic, or electrocardiographic findings. When moderate 
or severe pulmonary hypertension occurs (mean PPA > 40 mm Hg), 
symptoms are usually those associated with the underlying pulmonary 
disease. 
Most common symptoms are dyspnea on exertion, chronic 
cough with mucoid productive sputum (mainly in the morning hours), 
inconstant degrees of wheezing, and occasional cyanosis; clubbing of 
the fingers can be present. Moderate or severe pulmonary 
hypertension by itself due to idiopathic reasons (e.g., in patients with 
idiopathic pulmonary arterial hypertension) can result in only minimal 
or nonspecific symptoms.  
Along with exertional dyspnea and fatigue, some patients 
experience dizziness or even exertional syncope, which is due to the 
inability to increase cardiac output during exercise along with a 
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marked increase in pulmonary vascular resistance. Also, these patients 
can have chest pain because of right ventricular ischemia or main 
pulmonary artery stretching. 
When resting PPA is sufficiently raised, patients   may reach a 
point eventually at which the right ventricle won’t meet the need for 
increased stroke work without a significant raise in right heart filling 
pressures. The resultant increase in central venous pressure is related 
with evolving symptoms of right-sided heart failure, such as, right 
upper quadrant discomfort, nocturia, peripheral edema and easy 
fatigability. 
On examination, the patient is usually cyanotic and sitting 
upright with tachypnea, prominent accessory muscles of respiration, 
and arms extended holding the edges of the mattress. In COPD, pulsus 
paradoxus can be present. The chest would be hyperinflated. There 
can also be audible wheezing, mainly if the decompensation process 
has been relatively acute and combined with a superimposed 
respiratory infection. 
Sinus tachycardia is usually present, atrial and ventricular 
arrhythmias are also present. Evidence of fluid retention can include 
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dependent edema and ascites. The liver is enlarged and tender to 
palpation, and would be pulsatile, reflecting the presence of severe 
tricuspid regurgitation. Likewise, the neck veins are distended and, 
when tricuspid insufficiency is present, would show a large c-v wave 
with rapid y descent; also, there would be a prominent a wave 
indicating the raised force of right atrial contraction. 
On chest examination, there may be a left para sternal systolic 
lift, due to the over activity of the enlarged right ventricle, and a thud 
may be felt over the pulmonary area when the pulmonary valve closes. 
The heart sounds are usually difficult to hear if the patient has 
underlying COPD. The pulmonic component of the second heart 
sound (S2) would be accentuated and occurs earlier than usual, and so 
the normal splitting may be abolished and a single loud S2 would be 
heard. Normally not heard at the apex, the pulmonic component of S2 
can now be clearly heard. 
 A high-pitched systolic ejection click can be heard in the 
second and third left intercostal spaces just next to the sternum. It is 
usually followed by a soft, localized systolic ejection murmur which is 
produced by ejection of the stroke volume into a dilated pulmonary 
 30 
 
artery. An S3 gallop arising from the right side of the heart can be 
heard in the fourth and fifth interspaces next to the left of the sternum 
or even next to the xiphoid process. A presystolic S4 gallop can also be 
heard, reflecting the forcible contraction of the right atrium with 
expulsion of blood into the dilated and hypertrophied right ventricle.                   
Usually tricuspid regurgitation is present which results in a 
prominent blowing pansystolic murmur in the same location, which 
can increase somewhat with inspiration. When prominent pulmonary 
hypertension is present, a diastolic murmur of pulmonary 
incompetence can be heard; this murmur, which is known as Graham 
Steell's murmur, is a soft, blowing decrescendo diastolic murmur, 
mainly well localized to the second and third left intercostal spaces 
next to the sternum. 
Chest Radiograph 
The appearance of the chest radiograph depends mainly on the 
underlying cause for the presence of pulmonary hypertension. 
Usually, the main pulmonary artery segment is enlarged, together with 
large right and left descending pulmonary arteries. But, there is abrupt 
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tapering of the peripheral vessels, which results in disproportionately 
large central pulmonary arteries and attenuated distal vessels. 
A right descending pulmonary artery with a diameter greater 
than 16 mm indicates pulmonary hypertension. Enlargement of the 
right ventricle, which can be observed on echocardiography, is usually 
not appreciated on the chest radiograph. If lung hyperinflation is 
present, the overall diameter of the cardiac silhouette would not be 
increased, although the heart may have a globular appearance. Usually 
some encroachment of the retrosternal space by an enlarged right 
ventricle can be seen in a lateral view. 
Pleural effusions are not seen in patients presenting with pure 
cor pulmonale unless coexisting left ventricular dysfunction with 
failure are also present.. The visceral pleura plays little  role in pleural 
fluid turnover in the normal lungs, but does help as an important 
escape route for excess interstitial fluid that accumulates in the lungs 
at the time of the evolution of cardiogenic pulmonary edema. 
Pleural effusions may be expected in patients with chronic 
corpulmonale and elevated right heart filling pressures, as they have 
increased systemic venous pressures, which must increase capillary 
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pressures within the parietal pleura. Increased transudation of fluid 
into the parietal pleural interstitium and then into the pleural space can 
be expected. 
Failure to find pleural effusions under these circumstances 
reflects the capacity of the parietal lymphatics to significantly increase 
their fluid removal capacity, by almost 20-fold. These mechanisms 
would appear to be aided by the findings of a prospective study of 37 
patients who were admitted for congestive heart failure in whom the 
presence of pleural effusions matched with the values of pulmonary 
artery wedge pressure but not with that of the right atrial pressure. 
In another retrospective study of 18 patients with long-term   
pulmonary or right atrial hypertension or both, but with normal 
pulmonary artery wedge pressures, no pleural effusions were seen. 
But, patients have been observed with chronic cor pulmonale and 
acute exacerbation of cardiac decompensation which results from a 
superimposed respiratory infection who showed transient small pleural 
effusions during the acute episode. 
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Electrocardiogram  
 The electrocardiogram can be helpful in establishing the 
presence of chronic corpulmonale. Characteristically, the P wave 
have a “p pulmonale” pattern with right-axis deviation which results 
in an increase in its amplitude in leads II, III, and aVF to more than 
2.5 mm. The P wave can also be tall in the right precordial leads.                            
When   the   pulmonary arterial hypertension is moderate or 
severe, the more classic findings of right ventricular hypertrophy 
would dominate the electrocardiogram, which shows a prominent S 
wave in V5 and V6 with an R/S ratio of less than 1and tall R waves 
in V1 with an R/S ratio of more than 1. The electrocardiographic 
evidence of cor pulmonale in   COPD patients is a poor prognostic 
sign. 
 
Echocardiography  
Echocardiography is the most widely used and accepted 
screening tool for diagnosing the presence of pulmonary hypertension 
and the right ventricular structure and function monitoring. An 
echocardiographic examination can help the clinician in ruling out 
various non pulmonary causes of secondary pulmonary hypertension, 
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like aortic or mitral valve disease, left ventricular failure from 
coronary disease or dilated congestive cardiomyopathy, and 
congenital heart disease with left-to-right shunt. 
An estimation of the pulmonary artery systolic pressure can be 
evaluated in 36% to 86% of patients with pulmonary hypertension by 
the presence of tricuspid regurgitation and using continuous-wave 
Doppler to get the tricuspid regurgitant jet velocity.  (16) 
 The pressure gradient across the tricuspid valve between the 
right atrium and ventricle is evaluated using the modified Bernoulli 
equation (4v2), where v represents the tricuspid regurgitant jet 
velocity, and this value is then added to the right atrial pressure 
(estimated by the size and collapsibility of the inferior vena cava) to 
finally obtain  an estimate of the right ventricular systolic pressure, 
which equals the pulmonary artery systolic pressure in the absence of 
pulmonary valve stenosis. Also, there is   pulmonary valve 
insufficiency detectable by Doppler echocardiography in the presence 
of pulmonary hypertension, which allows an estimation of pulmonary 
artery diastolic pressure. The size of the right ventricle and the right 
atrium can be determined and the contractile state of the right ventricle 
can be assessed. 
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Flattening or leftward shift of the interventricular septum during 
systole indicates right ventricular pressure overload and 
interventricular septal flattening during diastole suggests right 
ventricular volume overload. If right heart filling pressure (which is 
equal to right atrial pressure) is increased, it is generally associated 
with the inferior vena cava dilatation, which won’t collapse with 
respiratory manoeuvre such as sniffing. 
Although right ventricular ejection fraction was the most 
commonly used index for assessing right ventricular function in the 
past, it is highly relied on loading conditions and cannot accurately 
reflect contractility.  Echocardiography is less accurate than   magnetic 
resonance imaging (MRI) and radionuclide angiography derived right 
ventricular ejection fraction methods. 
In a study of 32 patients with advanced lung disease, Schenk 
and colleagues observed that, among the many echocardiographic 
parameters, right ventricular end-diastolic area and fractional area 
change from the apical four-chamber view matched best with MRI-
derived right ventricular volume and ejection fraction, respectively. 
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Newer Doppler-derived indices of right ventricular function, 
right ventricular myocardial performance index (RVMPI) and the 
tricuspid annular plane excursion (TAPSE) have both been shown to 
have prognostic value in patients with idiopathic pulmonary arterial 
hypertension and other classes of pulmonary hypertension. 
Three-dimensional echocardiography is a better technique that 
could lead to a more definite assessment of right ventricular volume 
and ejection fraction; but, difficulties in delineation of the anterior 
wall and infundibular plane still need to be overcome. The presence of 
lung hyperinflation impairs the transmission of ultrasound and may 
result in suboptimal transthoracic echocardiographic imaging. 
The sensitivity and specificity of Doppler echocardiography to 
predict the presence of pulmonary hypertension would range from 
0.79 to 1.0 and from 0.6 to 0.98, respectively, and the actual echo-
Doppler–derived estimate of pulmonary artery systolic pressure can be 
imprecise when compared with right heart catheterization.  (17). 
If sufficient lung hyperinflation prevents adequate transthoracic 
examination, we can go for the transesophageal echocardiography 
(TEE) to rectify the problem. Usually patients in this stage are 
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intubated, and a transesophageal study probe may be slipped into the 
esophagus with ease. 
It is of value to note that the estimation of pulmonary artery 
systolic pressure via echo-Doppler alone might not fully address 
pulmonary hypertension, and  when therapies directed at the 
pulmonary vasculature are being planned, a diagnostic right heart 
catheterization must be considered. 
Computed Tomography 
Chest CT is usually used to visualize the pulmonary 
parenchyma in patients with respiratory disease. With this imaging 
modality, the size of the pulmonary artery would be measured, and in 
patients with moderate to severe pulmonary hypertension, an 
increased diameter of the pulmonary artery (>29 mm) may be 
measured. 
But, in a study of 65 patients with advanced idiopathic 
pulmonary fibrosis, the measurement of main pulmonary artery 
diameter on high-resolution chest CT is unable to differentiate 
between those who did or did not have pulmonary hypertension as 
diagnosed with right heart catheterization. So, CT does not seem to be 
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a reliable modality to screen for pulmonary hypertension.  But, dilated 
right heart chambers on contrast-enhanced CT imaging would suggest 
but not diagnostic of corpulmonale in patients with severe 
parenchymal lung diseases. 
Magnetic Resonance Imaging 
MRI is the most accurate method for evaluating right 
ventricular volume and ejection fraction. Compared with the normal 
left ventricular volume, the right ventricular volume is larger and the 
ejection fraction is lower. 
Phase-contrast MRI has the capability to accurately calculate 
flow characteristics, including valvular regurgitant fraction ,cardiac 
output, , and shunt fraction. Because of its capability to penetrate 
diseased lungs and its high temporal resolution, the image quality of 
MRI to view cardiac structures is superior to that of echocardiography, 
mainly in patients with advanced lung disease. 
Although relatively long image acquisition time, high cost, and 
lack of widespread availability limit its use when compared with 
echocardiography, cardiac MRI is being used increasingly as a 
standard tool for the evaluation of right ventricular structure and 
 39 
 
function in pulmonary arterial hypertension patients. Its application in 
patients with respiratory diseases and corpulmonale has still to be 
evaluated. (18). 
GENERAL ASPECTS OF DISEASE MANAGEMENT 
The general measures to be considered in the patients with 
pulmonary hypertension and corpulmonale are as follows. Treatment 
is also directed by the underlying diseases and the identification of any 
reversible causes on treatment.                                                  
Exercise and the Avoidance of Deconditioning 
In variable of the cause, patients with pulmonary hypertension 
and cor pulmonale should   maintain a active lifestyle. Regular, steady 
aerobic exercise should be advised and encouraged, and is usually best 
initiated under monitoring of a pulmonary or cardiac rehabilitation 
program. 
Oxygen Therapy 
Mainly in the management of patients with pulmonary 
hypertension, the avoidance of acute hypoxia is important, as hypoxic 
pulmonary vasoconstriction add up the burden on the right ventricle. 
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Measurements of arterial oxyhemoglobin saturation should be done at 
rest, during sleep, as well as during exertion. Levels of arterial oxygen 
saturation below 90 percent would require supplemental oxygen. 
Maintaining the adequate oxygen saturation would be difficult in 
those patients with severe pulmonary hypertension and a patent 
foramen ovale  allows right-to-left shunting. Supplemental oxygen has 
been shown to benefit patients with COPD. 
Two separate trials, that of the National Heart, Lung and Blood 
Institute (Nocturnal Oxygen Therapy Trial) and of the Medical 
Research Council have shown that intellectual function and survival of 
the COPD patients are enhanced in chronically hypoxemic patients 
(arterial PO2 under 55 mmHg) who are edematous, polycythemic 
(hematocrit greater than 55 percent), and show P pulmonale on the 
electrocardiogram. But, to be effective, oxygen must be delivered for 
at least 18 h per day—including at night, when arterial hypoxemia and 
respiratory acidosis intensify. 
Oxygen corrects hypoxic pulmonary vasoconstriction, and so 
decreasing vascular resistance and improving the cardiac output, 
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decreases renal vasoconstriction improving the urinary sodium 
excretion, and corrects tissue hypoxia by improving oxygen delivery. 
Supplemental oxygen should be administered to avoid arterial 
oxygen saturation below 90 percent. Supplemental oxygen is generally 
required for those with borderline levels of arterial oxygen saturation 
at sea level; increased oxygen flow rates are  needed for those who use 
oxygen therapy for the activities of daily life.  
Infection 
Acute respiratory infection may induce right heart failure in 
patients with corpulmonale. Acute exacerbations are a particular and 
usually recurrent problem for patients with pulmonary hypertension 
due to COPD. Worsened hypoxia and/or respiratory acidosis may 
aggravate pulmonary hypertension, and precipitate cardiac 
arrhythmias. Treatment for pulmonary infection must be given 
promptly and include oxygen and antibiotic therapies. 
Airways obstruction can increase intrathoracic pressures and 
influence the venous return causing hepatic congestion and peripheral 
edema. Bronchodilators should be given to relieve airways obstruction 
and relieve hypoxia. Immunizations against influenza and 
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pneumococcal pneumonia are main preventive measures in all patients 
with pulmonary hypertension and corpulmonale. 
Fluid Management and Diuretics 
To avoid fluid overload is main stay of the management of    cor 
pulmonale of any cause. Patients must be trained regarding 
appropriate dietary habits and must restrict sodium intake in order to 
slow down fluid retention and the development of right heart failure. 
Digitalis and Theophylline 
The role of cardiac glycosides in treating right heart failure is 
unsettled. Nevertheless, digoxin is regularly used empirically, mainly 
when pulmonary hypertension is accompanied with atrial fibrillation. 
Dysrhythmias 
Dysrhythmias occur infrequently with cor pulmonale. Common 
precipitating mechanisms are anxiety and excessive use of 
bronchodilators. Sometimes, a bout of respiratory failure induces an 
episode of atrial tachycardia, a wandering pacemaker nodal rhythm, 
atrial flutter, or fibrillation. Stimuli that induce intense adrenergic 
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discharge raise the possibility of adverse effects from therapeutic 
agents, such as digitalis. 
Arrhythmias in cor pulmonale are transient and disappear with 
discontinuation of the precipitant (e.g., an acute respiratory infection.). 
But, arrhythmias can be life threatening if they happen in the presence 
of arterial hypoxemia, disturbances in acid-base balance, and 
heightened sympathetic activity. The happening of such a life-
threatening arrhythmia, usually ventricular fibrillation, is mainly 
during a bout of acute respiratory failure, with its accompanying 
disturbances in gas exchange and electrolyte imbalances. 
 Respiratory alkalosis, induced by mechanical hyperventilation 
and accompanied by hypokalemia, may also be a precipitating 
mechanism. 
Pulmonary Vasodilators in non-PAH Forms of Pulmonary 
Hypertension 
Many vasodilator drugs are under use in the attempt to decrease 
pulmonary vascular resistance and enhance right heart function in     
corpulmonale. But, except for some patients with pulmonary arterial 
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hypertension, the use of vasodilators doesn’t have been of benefit in 
corpulmonale. 
Results in patients with corpulmonale due to COPD, for 
example, have been mixed and, successful only in the short term. For 
example, the use of calcium channel antagonists in COPD patients can 
worsen hypoxia and ventilation-perfusion mismatch. In addition, the 
depressant effects of these agents on cardiac inotropy can significantly 
worsen right heart function (19). 
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MATERIALS AND METHODS 
 STUDY CENTRE 
Institute of thoracic medicine, Chetpet and Department of 
Thoracic Medicine, Rajiv Gandhi Government General Hospital, 
Chennai.   
Department of Cardiology, Rajiv Gandhi Government General 
Hospital, Chennai. 
STUDY DESIGN 
Observational  study. 
STUDY PERIOD 
From February 2012 to   November 2012 
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INCLUSION CRITERIA 
1. known case of COPD patients 
2. newly diagnosed COPD patients 
3. age group >30 years 
 
EXCLUSION CRITERIA 
1. PT Sequelae 
2. known diabetics 
3. known Hypertensives 
4. h/o ischaemic   cardiac disease and  valvular    heart 
disease. 
5. known case of Bronchial asthma and  Interstitial lung 
disease. 
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METHODOLOGY 
About 51 COPD patients with unknown severity who have  
attended as  out-patients  in  Institute of thoracic  medicine, Chetpet 
and Department of thoracic medicine, Rajiv Gandhi  Government 
general  hospital, Chennai were subjected to following    
investigations .The study was done within a time period of ten months. 
Written consent was obtained from the patients in their regional 
language, after explaining the details of the study. Complete history 
regarding the symptoms, past history, smoking history, occupational 
history and other associated illnesses were taken and noted in a 
proforma. Clinical examination of the patients had been done. 
Smoking index  were  categorized in male patients as follows: 
<150 - mild 
150  -   300 - moderate 
>300 - severe. 
In the females, history regarding passive smoking and biomass 
fuel usage were obtained. 
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Patients were then subjected to routine blood investigations like 
complete blood count, renal function tests, liver function tests, routine 
blood sugar, blood pressure, ECG, Chest X ray PA and CT chest, 
wherever indicated. 
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The patients who met the inclusion and exclusion criteria are 
subjected to spirometry. 
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ECHOCARDIOGRAPHY: 
Echocardiographic assessment of right ventricular and left 
ventricular function were done using  
 Systolic pulmonary arterial pressure 
 Tricuspid annular plane systolic excursion(TAPSE) 
 LV Ejection fraction 
 RV & LV diastolic function  
 Tei index  
 Respiratory  variation (5,6) 
The ECHOCARDIOGRAPHY was done to all the patients in 
the Department of Cardiology, Government General Hospital, 
Chennai and the reports were obtained in a regular format. 
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SYSTOLIC PULMONARY ARTERIAL PRESSURE (SPAP)  
Pulmonary hypertension is defined as SPAP >30mmHg. It can 
be categorized as follows: 
 Mild  - 30 to 40mmHg 
 Moderate - 40 to 60mmHg 
 Severe - > 60mmHg  
               
It is calculated by the formula, 
SPAP=TRPG+RA   Pressure. 
 
 
 
 
 
 
 
 
 
 
DOPPLER ECHOCARDIOGRAPHIC determination of systolic 
pulmonary arterial pressure (SPAP). Spectral continuous –wave Doppler 
signal of tricuspid regurgitation signifying Right ventricular (RV)-Right 
atrial (RA) pressure gradient. 
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 RA pressure:RA pressure can be estimated by IVC diameter and 
the presence of inspiratory collapse. When RA pressure increases, 
it would be transmitted to IVC, which results in reduced collapse 
with inspiration and IVC dilation. Specific values of RA pressure 
should be used in the SPAP determination.IVC diameter of ≤ 2.1 
cm which collapses >50% with a sniff indicates a normal RA 
pressure of 3 mm Hg (0-5 mmHg), but an IVC diameter >2.1 cm 
which collapses <50% with a sniff indicates a high RA pressure of 
15 mm Hg(range of 10-20 mm Hg). In indeterminate cases, an 
intermediate value of 8 mmHg(range of 5-10 mmHg) can be used. 
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View of Inferior vena cava. The solid line which indicates the 
diameter measured perpendicular to the long axis of the IVC at end-
expiration proximal to the ostium of the right atrium. 
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TAPSE (TRICUSPID ANNULAR PLANE SYSTOLIC 
EXCURSION) : 
TAPSE is a method which measures the distance of systolic 
excursion of the RV annular segment along its longitudinal plane, by a 
standard apical 4-chamber window. Its acquired by placing a M-mode 
cursor through the tricuspid annulus and then measuring the 
longitudinal motion of the annulus at the peak systole. 
Value < 1.6cm indicates Right ventricular Systolic dysfunction. 
 
 
 
 
Ejection Fraction : 
         Value < 55% indicates left ventricular systolic dysfunction . 
       
 
 
MEASUREMENT OF TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION (TAPSE) 
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RESPIRATORY VARIATION: 
Respiratory variation is said to be significant when the 
difference in ventricular filling during inspiration and expiration is > 
40% in right side and >25% in left side. 
VENTRICULAR DIASTOLIC FUNCTION: 
E/A Ratio: 
Ratio of peak flow velocity across AV valve during early rapid 
filling wave (E) and during atrial contraction (A). 
Normal value: Right - 0.8 - 2.1 
Left - age 41 to 60  0.78 - 1.78 
age > 60  0.6  - 1.32  
E/E'   Ratio : 
Normal value :  Right - < 6 
Left - < 6.7  
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TEI INDEX : 
Tei index is a global estimate of both systolic and diastolic 
functions of the ventricle. 
The mean normal value of the Tei index is 0.28 for the right 
ventricle and 0.54 for the left ventricle. 
 
                
 
 
 
 
 
 
 
 
 
CALCULATION OF TEI INDEX 
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The right sided MPI may be obtained by two methods: The tissue 
Doppler method and the pulsed Doppler method. In the pulsed 
Doppler method, all time intervals are evaluated from a single beat by 
pulsing the tricuspid annulus. In the pulsed Doppler   method, ET is 
measured with pulsed Doppler of RV outflow (the time calculated 
from the onset to the cessation of flow) and the tricuspid closure-
opening time is measured with either pulsed Doppler of the tricuspid 
inflow or continuous Doppler of the TR jet.  
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RESULTS 
The results of the study are as follows: 
Total No. of COPD patients enrolled in our study-51. 
  
 
 
 
 
 
 
 
 
 
 
 
No. of Males and Females participated 
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The patients are categorized according to the severity assessed 
by spirometry based on GOLD guidelines, as follows: 
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MEASUREMENT OF PULMONARY HYPERTENSION BY 
CALCULATING SPAP AND ITS CORRELATION WITH 
COPD SEVERITY. 
 
Pulmonary hypertension is present in 33.3% (2/6), 28.6% 
(4/14), 82.3% (14/17) and 71.4% (10/14) cases of mild, moderate, 
severe and very severe obstruction respectively. 
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RIGHT VENTRICULAR SYSTOLIC FUNCTION AS 
ASSESSED BY TAPSE. 
 
Normal TAPSE values are seen in all the patients invariable of 
the COPD severity. 
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RIGHT VENTRICULAR DIASTOLIC FUNCTION AS 
ASSESSED BY E/A AND E/E’ RATIO AND ITS 
CORRELATION WITH COPD SEVERITY 
 
The right ventricular Diastolic dysfunction has no relation to the 
severity of COPD in this study. 
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THE RESPIRATORY VARIATION IN RIGHT VENTRICLE 
CORRELATED WITH COPD SEVERITY 
 
 
The abnormality in Right ventricular filling during respiratory 
variation increases, when the severity in COPD increases. 
 
 
 64 
 
RIGHT VENTRICULAR GLOBAL FUNCTION MEASURED 
BY TEI INDEX COMPARED WITH COPD SEVERITY AS 
FOLLOWS: 
 
Right ventricular global dysfunction (using Tei index ) are  
33.3%,42.9%,76.5% and 85.7% in mild, moderate, severe and very 
severe obstruction respectively. 
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THE LEFT VENTRICULAR SYSTOLIC FUNCTION AS 
ASSESSED BY EJECTION FRACTION WHEN CORRELATED   
WITH COPD SEVERITY. 
Although the mean value of the Ejection fraction decreases as 
the COPD severity increases from 72.0% to 67.6%, all the values 
comes within the normal range. 
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LEFT VENTRICULAR DIASTOLIC FUNCTION MEASURED 
BY E/A & E/E’ RATIO WHEN COMPARED     WITH COPD 
SEVERITY. 
 
The left ventricular diastolic dysfunction have no correlation 
with the COPD disease severity. 
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THE CORRELATION OF LEFT VENTRICULAR FILLING ON   
RESPIRATORY VARIATION WITH COPD SEVERITY. 
 
As the COPD severity increases, the abnormality in left 
ventricular filling  on  respiratory  variation  increases. 
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THE LEFT VENTRICULAR GLOBAL FUNCTION 
MEASURED BY TEI INDEX IN RELATION WITH THE   
COPD SEVERITY. 
 
 
The left ventricle global function does not correlate with COPD 
severity in this study. 
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THE AVERAGE HAEMOGLOBIN VALUES PLOTTED 
ACCORDING TO THE COPD SEVERITY. 
 
 
The haemoglobin values in all the cases are in the low normal 
range and no value showed polycythemia. 
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THE SMOKING INDEX OF THE STUDY POPULATION 
WHEN PLOTTED AGAINST THE COPD SEVERITY. 
 
 
 
Of the 47 male cases, 15 mild, 16 moderate and 16 severe 
categories of smoking index are distributed unevenly among 
individuals. In the females, history of passive smoking and biomass 
fuel usage are seen. 
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DISCUSSION 
 Chronic Obstructive Pulmonary Disease have been proved to be 
a systemic disease rather than a pulmonary disease, as it was identified 
in the past. 
Cardiovascular system is mainly affected among systems other 
than lung itself. Cardiac dysfunction has been well known to 
complicate COPD of any severity and also remain to be the main 
cause of mortality in these patients. Changes in cardiovascular system 
both in mild and moderate COPD has been demonstrated in many 
studies and also well documented in literature. 
Right ventricle and the pulmonary blood vessels are the major 
parts affected in patients with COPD during its clinical course. The 
structure of pulmonary blood vessels would be affected, leading to 
intimal thickening and medial hypertrophy which further increases the 
pulmonary arterial pressure and so, pulmonary hypertension. The raise 
in pulmonary arterial pressure has been reported in 30-80% of COPD 
patients, using pulmonary arterial catheterisation. 
 Pulmonary hypertension , in turn augments the right ventricular 
afterload leading to the dilatation and hypertrophy of right ventricle. 
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In addition to these, left ventricle also have been known to be  affected 
, either alone or along with right ventricle. 
This study mainly focuses on the assessment of cardiovascular 
changes in COPD patients and its correlation with the disease severity. 
In south india, studies related to this are not found easily. The salient 
features of this study are, 
 Based on GOLD guidelines, the no. of Mild, Moderate, Severe 
and Very severe COPD patients participated in the study are 
6,14,17 and 14 respectively using spirometry. 
 Pulmonary hypertension is present in 33.3% (2/6), 28.6% 
(4/14), 82.3% (14/17) and 71.4% (10/14) cases of mild, 
moderate, severe and very severe obstruction respectively. This 
reveals that pulmonary hypertension is present more commonly 
in the severe cases than in the milder cases. 
 Although normal values of TAPSE and ejection fraction are 
observed indicating normal ventricular systolic function, the 
ejection fraction diminishes with the disease severity. 
 Right ventricular global dysfunction (using Tei index ) are  
33.3%,42.9%,76.5% and 85.7% in mild, moderate, severe, and 
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very severe obstruction respectively, which shows that right 
ventricular dysfunction increases with COPD disease severity. 
 The left ventricular global dysfunction does not correlate with 
the disease severity. 
 
In contradiction to these results, A study published in the Respir 
Med in the year 2010 revealed that COPD patients have right 
ventricular dysfunction related to airways obstruction and sub-clinical 
left ventricular dysfunction related to arterial stiffness. This study also 
explains that cardiovascular changes are seen in COPD even during 
mild airways obstruction. (2) 
Another study published in Eur J Echocardiography in 2006 
implied Tei index as a main parameter in Echocardiography for 
measuring right ventricular dysfunction in COPD. This showed the 
presence of both right and left ventricular dysfunctions in patients 
with COPD. (3) 
A study published in the journal LUNG INDIA in the year 2011 
observed that the pulmonary hypertension, right ventricular and left 
ventricular dysfunction are more prevalent and their occurrence 
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correlated well with the severity of COPD. This study is based mainly 
on Echocardiographic findings. (4) 
 The haemoglobin values in all the cases in are in the low normal 
range and no value showed polycythemia. 
 
  CLINICAL IMPLICATIONS: 
Until the right ventricle fails, preoccupation with the underlying 
pulmonary disease may divert attention from the presence of 
pulmonary hypertension and the development of right ventricular 
enlargement by masking of clinical manifestations.  
In all patients with COPD invariable of its severity, by 
detecting, close monitoring and appropriately treating the 
cardiovascular abnormalities, the morbidity and mortality can be 
reduced. Echocardiography serves as a main tool in assessing the 
cardiovascular changes in patients with COPD and should be 
considered in all the patients irrespective of its severity. 
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CONCLUSION 
 
1. There is increase in right ventricular global dysfunction and also 
pulmonary hypertension   in COPD patients as the severity 
increases. 
2. All COPD patients should undergo cardiac evaluation using 
echocardiogram to detect early cardiac abnormalities so as to 
prevent cardiac mortality and morbidity. 
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                        PROFORMA 
 
NAME    : 
AGE        : 
SEX         : 
HEIGHT : 
WEIGHT: 
SMOKER:  
If yes, no. of pack years: 
H/O PT, DM, SHT: 
H/O IHD: 
CLINICAL FEATURES: 
                                  
                            BP:                    PR: 
 
Hb% : 
RFT/LFT : 
 
X-RAY CHEST: 
 
ECG  : 
 
SPIROMETRY: 
  
ECHOCARDIOGRAPHY 
RWMA                       YES               NO 
If yes,  
LVd                                          LVs  
EF 
                       Exp                    Insp 
LAOT         E          A               E           A 
RAOT        E          A               E           A 
PV Flow     S           D          AR 
IVC d        End Exp                    Insp 
TAPSE 
TDI   
 Tricuspid annulus  
S          E’        A’        IVCT          IVRT    
 Mitral annulus 
S          E’        A’        IVCT          IVRT 
RV MPI    -        PET 
                         TVC-TVO 
LVMPI     -         AET 
                         MVC-MVO 
LV systolic function 
PAH 
TR             Severity             Gradient 
  
INFORMATION SHEET 
 Your participation has been accepted.  
 We are conducting a study on COPD patients among patients 
attending Government  
 General Hospital, Chennai and for that your participation may 
be valuable to us.  
 The purpose of this study is to assess the cardiovascular 
changes in COPD patients easily with  
 The help of certain investigations like spirometry, blood 
investigation, chest x ray/CT chest, ECG and ECHO. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally 
identifiable information will be shared.  
 Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; 
your decision will not result in any loss of benefits to which you 
are otherwise entitled.The results of the special study may be 
intimated to you at the end of the study period or during the 
study if anything is found abnormal which may aid in the 
management or treatment.  
 
 
 
Signature of investigator    Signature of participant  
       
Date: 
 
  
 
  
 
  
 
  
 
 
